Development of novel treatments based on T cell receptors
Research type
Research Study
Full title
Development of novel treatments based on T cell receptors
IRAS ID
129424
Contact name
Samantha Paston
Contact email
Sponsor organisation
Immunocore Ltd
Duration of Study in the UK
5 years, 0 months, 1 days
Research summary
Recognition molecules (receptors) on the surface of T cells, one of a family of white blood cells that form an integral part of the human immune system, play an important role in the recognition of diseased cells. Recognition of diseased cells is a vital part of the natural defence against cancer. T cells obtained from fresh human blood can be isolated by getting them to stick to cancerous cells that they recognise. These isolated cells can then be engineered in various ways to attach themselves to tumour cells and kill them. This may in turn lead to new safer treatments for different kinds of cancer.
T cells can only be obtained from fresh human blood from volunteers. Further, to be able to maintain and test cultures of T cells requires ongoing, fresh supplies of white blood cells termed feeder cells. Cells are also required to test the potency and safety of these new treatments.
This study is designed to ensure that an adequate supply of T cells is available to support the research into potential new treatments for cancer.REC name
South Central - Oxford A Research Ethics Committee
REC reference
13/SC/0226
Date of REC Opinion
29 Jul 2013
REC opinion
Further Information Favourable Opinion